Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy

Journal of Rheumatology

Volumn 42, Issue 1, 2015, Pages 21-30

  Jadon, Deepak R ^b   Nightingale, Alison L ^c   McHugh, Neil J ^d   Lindsay, Mark A ^c   Korendowych, Eleanor ^a   Sengupta, Raj ^b  

^a Department of Rheumatologist ^*  (Canada)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Arthritis; Biological markers; Dickkopf 1; Matrix; Metalloproteinase; Psoriatic; Psoriatic spondyloarthritis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLONY STIMULATING FACTOR 1; DICKKOPF 1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STROMELYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL MARKER;

BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE TURNOVER; CARTILAGE DEGENERATION; DISEASE SEVERITY; HUMAN; LONGITUDINAL STUDY; OUTCOME VARIABLE; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PSORIATIC ARTHRITIS; PSORIATIC SPONDYLOARTHROPATHY; REVIEW; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; BLOOD; BONE REMODELING; PHYSIOLOGY;

ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BONE REMODELING; HUMANS; SPONDYLARTHROPATHIES;

EID: 84920465536     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140223     Document Type: Review

References (38)

1. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28:138-43.
2. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994;37:1115-26.
3. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003;29:803-18.
4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:1-28.
5. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
6. Moll J, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
7. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 Suppl 2:ii1-44.
8. Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, et al. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. J Rheumatol 2013;40:653-62.
9. Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 2013;72:83-8.
10. Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology 2010;49:1399-405.
11. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010;12:R164.
12. Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007;56:2919-28.
13. Critical appraisal skills programme: making sense of evidence. 11 questions to help you make sense of a case control study. [Internet. Accessed September 30, 2014.] Available from: calder.med.miami.edu/portals/ebmfiles/UM%20CASP%20 Case-Controls%20Assessment%20Tool.pdf.
14. Ciacli C, Puschita M, Drugarin D, Solovan C, Gurban CV, Cotoraci C. [Bone turnover markers evaluation in psoriatic arthritis]. [Article in Romanian] Rev Med Chir Soc Med Nat Iasi 2008;112:635-40.
15. Ciacli C, Puşchitə M. RANKL/RANK/OPG molecular complex- control factors in bone remodeling in psoriatic arthritis. Rev Med Chir Soc Med Nat Iasi 2011;115:354-60.
16. Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008;27:443-7.
17. Skoumal M, Haberhauer G, Fink A, Steiner A, Klingler A, Varga F, et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: A marker for unknown peripheral joint involvement? Clin Exp Rheumatol 2008;26:1087-90.
18. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;48:3085-95.
19. Lata S, Cuchacovich R, Hagan J, Patel N, Espinoza LR. Do adipocytokines play a role in bone turnover in spondyloarthropathies? J Invest Med 2010;58:443.
20. Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clinical Rheumatol 2010; 29:1301-9.
21. Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm Ther 2006;31:149-52.
22. van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One 2010;5:e12556.
23. Grcevic D, Jajic Z, Kovacic N, Lukic IK, Velagic V, Grubisic F, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37:246-56.
24. Shibata S, Tada Y, Komine M, Hattori N, Osame S, Kanda N, et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci 2009;53:34-9.
25. Hofbauer LC, Schoppet M, Christ M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 2006;45:1218-22.
26. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
27. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-93.
28. Franck H, Ittel T. Serum osteocalcin levels in patients with psoriatic arthritis: An extended report. Rheumatol Int 2000;19:161-4.
29. Sharif M, George E, Dieppe PA. Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Ann Rheum Dis 1996;55:47-51.
30. Magaro M, Altomonte L, Mirone L, Zoli A, Tricerri A. Serum osteocalcin as an index of bone turnover in active rheumatoid arthritis and in active psoriatic arthritis. Clin Rheumatol 1989;8:494-8.
31. van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: A review of scoring methods. Ann Rheum Dis 2005;64 Suppl 2:ii61-4.
32. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56:3236-47.
33. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
34. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886-90.
35. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Euro J Endocrinol 1999;140:332-7.
36. Ritchlin C. Biomarker development in psoriatic arthritis. J Rheumatol Suppl. 2012 July;89:57-60.
37. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
38. Chandran V. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis. J Rheumatol Suppl. 2012 July;89:65-6.